Despite widespread criticism, a new report finds the Food and Drug Administration made useful changes to a controversial program that provides access to experimental medicines. However, the agency still needs to do a better job of explaining how patient side effect data can influence drug approval decisions, according to the U.S. Government Accountability Office analysis.
Not surprisingly, the findings prompted the same sort of bickering sparked by the program, itself.
About the Author Reprints
